According to the current (2015) recommendations of Global Initiative for Asthma (GINA) dealing under the auspice of World Health Organization (WHO) and in line with registered by EMA in EU as well as in Poland Summary of Product Characteristics (SmPC) [1] Polish Society of Allergology considers, that there is a need of modification of inclusion criteria to Therapeutic Program for treatment of severe IgE-mediated allergic asthma, which is a service guaranteed by National Health Found (NHF) ( Table 1 presents the proposals of changes). Currently inclusion criteria are very restrictive, limiting access to the treatment for many groups of patients, especially children, who could benefit from biological treatment. Scientific evidence from clinical [2] as well as observational [3] trials consistently show a significant advantage from early introduction of biological treatment in eligible patients before development of complications resulted from severe course of disease, including airflow limitation, life -threatening exacerbations or adverse reactions after systemic therapy with corticosteroids (CS), among others hypertension, osteoporosis, cataract, glaucoma, metabolic syndrome and diabetes as well as growth inhibition and puberty disorders in children. 1 . Inhaled route of corticosteroids administration is always safer than oral, taking into consideration lower systemic exposure, leading to the lower risk of after-steroids complications. This is extremely important in group of patients susceptible for systemic CS, such as children and adolescent as well as diabetic patients, with metabolic syndrome, osteoporosis and other serious complications after CS therapy. If, according to the treating physician's opinion, there is more beneficial to use in the first line the nebulization with high doses of ICS in a patients due to high risk of steroids adverse reactions, this therapy should be accepted, as there is evidence of its clinical equivalence compare to OCS [6−9] . According to the suggestions of Polish Society of Allergology experts, nebulization with ICS dose of over 2000 mcg/day should be considered as clinically relevant. Additionally, one should remember about the patients who continuously take systemic CS in order to prevent the exacerbations. Chronic therapy with OCS is heavily burdened with the risk of adverse reactions. Introduction of biological therapy for this group of patients gives a chance for limiting of demand of OCS, and sometimes even permanent discontinuation of that therapy [10−12] . 5. To increase the spirometric threshold from < 60% of expected value < 80% of expected value or to the best personal value for the patients older than 12 years, and to not establish any spirometric criterion for children between 6−12 years. This is in line in SmPC statement [2] . In the recent revision of their guidelines GINA experts removed the spirometric criterion from current asthma control [1], therefore it is not taken into consideration during treatment schedule planning, and omalizumab itself has no bronchodilating effect and improvement of lung function is not an expected result of treatment. Decreasing of lung function below 60% of expected value is a future high risk factor and is commonly observed in patients with long-lasting severe asthma, in which obstructive changes resulted from remodeling are irreversible. The aim of treatment of patients within Therapeutic Program should be prevention of such states rather than waiting for severe airway limitation, hence the increasing of threshold to < 80% as in SmPC seems to be justified. 6. To leave other criteria without any changes.
It should be clearly emphasized, that the introduction of Therapeutic Program of treatment of severe IgE-mediated asthma in 2013 and reimbursement from public sources was an indubitable success of Country Consultant for Allergology, Polish Society of Allergology, covering allergologists and patients suffering from severe asthma, with their continuous efforts as well as Ministry of Health and National Health Found. This program enabled wider access to biological treatment for patients with severe asthma and moved Poland closer to the standards accepted in other UE countries. Each and every patient, who meets inclusion criteria can be treated within the program, without any restrictions of eligible patient's' number. Currently there are 372 patients within the program. Since the beginning of the Program only 40 patients were excluded from treatment due to lack of significant improvement or other reasons, which confirms the high clinical effectiveness of the drug [13] . Therefore, making available this treatment to the bigger group of patients with severe asthma could give a chance for better quality of life to bigger number of patients as well as their families, and it could limit the healthcare system burden connected to www.pneumonologia.viamedica.pl the treatment of disease acute exacerbations and adverse reactions of therapy with CS. Estimated number of patients with severe asthma, eligible to immunological criteria according to the program Criteria is app. 1000 [14] , so there is no expectations of uncontrolled increasing of number of program's participants after introduction of suggested changes. 
